Articles Found

Page: 1 2 3 4 5 6 7 8 9 10 ... Next »

Recent Articles  Industry   Published  Ono Pharma Enters into a Drug Discovery Partnership with Mediar Therapeutics to Create Novel Antibody Therapeutics for Fibro-inflammatory Diseases Pharma / BioTech / Nutrition 2026/08/06 More OPDIVO® Intravenous Infusion Approved in South Korea for the Treatment of Resectable Non-Small Cell Lung Cancer Pharma / BioTech / Nutrition 2026/08/04 More Ipsen Completes Acquisition of Memo Therapeutics AG, Adding First-in-class Asset to Ipsen’s Rare Disease Pipeline Pharma / BioTech / Nutrition 2026/07/22 More SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System Pharma / BioTech / Nutrition 2026/07/21 More IQIRVO® Demonstrates Statistically Significant Improvement in ALP Normalization in Patients with PBC in Phase IIIb ELSPIRE Study Pharma / BioTech / Nutrition 2026/07/13 More Dysport® is the First Botulinum Toxin to Achieve Positive Topline Phase III Results in Both Episodic and Chronic Migraine Pharma / BioTech / Nutrition 2026/07/09 More STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development Pharma / BioTech / Nutrition 2026/07/08 More Ipsen to Acquire Memo Therapeutics AG - Adding First-in-class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio Pharma / BioTech / Nutrition 2026/07/01 More Ipsen to Acquire Kartos Therapeutics, Expanding Hemato-oncology Late-stage Pipeline Pharma / BioTech / Nutrition 2026/06/29 More Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement Pharma / BioTech / Nutrition 2026/06/11 More Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con Pharma / BioTech / Nutrition 2026/05/28 More Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity Pharma / BioTech / Nutrition 2026/05/20 More Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium Pharma / BioTech / Nutrition 2026/05/14 More SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure Pharma / BioTech / Nutrition 2026/04/28 More Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma Pharma / BioTech / Nutrition 2026/04/22 More

---

Page: 1 2 3 4 5 6 7 8 9 10 ... Next »